Related Experiment Video

Updated: Jun 16, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Biological impact of freezing Plk1 in its inactive conformation in cancer cells

Sarah Keppner1, Ewgenij Proschak, Manfred Kaufmann

  • 1Department of Obstetrics and Gynecology, Medical School, Goethe-University, Frankfurt, Germany.

Cell Cycle (Georgetown, Tex.)
|February 9, 2010
PubMed

Insights

A novel type II inhibitor, SBE13, targets human polo-like kinase 1 (Plk1), a key regulator overexpressed in tumors. This Plk1 inhibitor effectively reduces cancer cell proliferation and induces apoptosis, suggesting potential for new cancer therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Human polo-like kinase 1 (Plk1) is crucial for mitosis and frequently overexpressed in human tumors.
  • Plk1 overexpression correlates with poor prognosis and tumor aggressiveness, making it a therapeutic target.
  • Kinase inhibitors include type I (active conformation) and type II (inactive conformation) inhibitors.

Purpose of the Study:

  • To evaluate the efficacy of SBE13, a type II Plk1 inhibitor, in inducing cancer cell death.
  • To assess the selectivity of SBE13 against other kinases.
  • To explore the potential of targeting Plk1's inactive conformation for cancer therapy.

Main Methods:

  • Kinase assays
  • Western blot analyses
  • FACScan analyses
  • Caspase assays
  • Immunofluorescence studies

Main Results:

  • SBE13 inhibited Plk1 activity.
  • Lower SBE13 concentrations delayed cell cycle progression; higher concentrations induced G2/M arrest and apoptosis.
  • Abnormal mitotic figures were observed.
  • SBE13 demonstrated selectivity, not affecting Plk2, Plk3, or Aurora A kinase activity.

Conclusions:

  • SBE13 effectively inhibits Plk1 and induces cancer cell death through cell cycle arrest and apoptosis.
  • The selectivity of SBE13 for Plk1's inactive conformation highlights its potential as a targeted cancer therapeutic.
  • Targeting the inactive conformation of Plk1 with type II inhibitors represents a promising strategy for cancer drug development.

More Related Videos

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...